DURHAM, N.C., September 13, 2017 — Premier Research’s head of patient engagement will address patients’ emerging role in the development of novel drugs at the Global Genes RARE Patient Advocacy Summit in Irvine, California.

Juliet Moritz, the CRO’s Executive Director for Patient Engagement and Strategic Development, will join Alvin Shih, CEO of the biotech company Enzyvant, at 10:30 a.m. Thursday, September 14, to present The R&D Roadmap and the Growing Role of Patients.

Rare disease patients, active partners in pharmaceutical R&D for years, have become foundational within research labs, clinical trials, and the regulatory process. Ms. Moritz and Dr. Shih will discuss approval pathways for new rare disease therapies and the many ways patients are influencing the process.

About Premier Research

Premier Research is a leading clinical development service provider that helps highly innovative biotech and specialty pharma companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,100 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.